Evaluation of the 7<sup>th</sup>edition of the TNM classification in patients with resected esophageal squamous cell carcinoma

Wang, Jia; Wu, Nan; Zheng, Qingfeng; Yan, Shi; Lv, Chao; Li, Shaolei; Yang, Yue

doi:10.3748/wjg.v20.i48.18397

Cited by 39 publications

(36 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[23][24][25] In the largest report of 1033 Chinese patients with resected esophageal squamous cell carcinoma, the overall 5-year survival rates were 84.9%, 70.9%, 56.2%, 43.3%, 37.9%, 23.3% and 12.9% in patients with pStage IA, IB, IIA, IIB, IIIA, IIIB and IIIC disease, respectively. Some long-term surgical results of esophageal cancer are available from the large series that utilized the 7th edition TNM classification system.…”

Section: Discussionmentioning

confidence: 99%

“…Some long-term surgical results of esophageal cancer are available from the large series that utilized the 7th edition TNM classification system. [23][24][25] In the largest report of 1033 Chinese patients with resected esophageal squamous cell carcinoma, the overall 5-year survival rates were 84.9%, 70.9%, 56.2%, 43.3%, 37.9%, 23.3% and 12.9% in patients with pStage IA, IB, IIA, IIB, IIIA, IIIB and IIIC disease, respectively. 25 In the latest comprehensive registry of esophageal cancer of Japan in 2008 according to the 6th edition of the TNM classification system, 26 the 5-year survival rates of 2657 patients 28 and a study of the 5-year rate of symptomatic first recurrence after MIE conducted by Thomson et al.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival outcomes of 220 consecutive patients with three-staged thoracoscopic esophagectomy

et al. 2015

View full text Add to dashboard Cite

Patients with thoracic esophageal cancer are often treated by minimally invasive esophagectomy. However, the long-term survival benefits of minimally invasive esophagectomy remain unclear. Two approaches are available for thoracoscopic surgery: one with the patient in the left lateral decubitus position (LLDP), and the other with the patient in the prone position (PP). We investigated the survival benefit of thoracoscopic esophagectomy according to the tumor stage and patient position during the thoracoscopic procedure. We reviewed the records of 220 consecutive patients with esophageal cancer treated from 1998 to 2012. In total, 146 and 74 patients were treated with thoracoscopic esophagectomy in the LLDP and PP, respectively. No patients were initially proposed to be candidates for esophagectomy by thoracotomy during the study period. Data collection was performed with a focus on survival and recurrent disease. Among all the 220 patients, the overall 5-year survival rates were 83.7%, 74.1%, 45.5%, 78.6%, 44.2%, 29.4% and 24.3% in the patients with pStage IA, IB, IIA, IIB, IIIA, IIIB and IIIC disease, respectively. Despite the greater number of dissected mediastinal lymph nodes in the PP procedure, there were no significant differences in the survival curves between the LLDP and PP procedures. The long-term results of thoracoscopic esophagectomy are comparable and acceptable. The PP procedure was not confirmed to offer a superior survival benefit to the LLDP procedure in this retrospective study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Survival outcomes of 220 consecutive patients with three-staged thoracoscopic esophagectomy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Surgery is usually done after neoadjuvant treatment. The overall survival of ESCC is 36.4% (53). Prognosis depends on the depth of mural invasion, tumor regression grade and lymph node metastasis.…”

Section: Esophageal Squamous Cell Carcinomamentioning

confidence: 99%

Pathology of esophageal cancer and Barrett’s esophagus

Jain

Dhingra

2017

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

Esophageal cancer is a serious malignancy with high mortality. The two common distinctive pathologic subtypes of esophageal cancer are squamous cell carcinoma and adenocarcinoma. These differ with regards to etiology, ethnic distribution, pathogenesis, and location in the esophagus. The precursor lesions are also unique to each subtype. Squamous cell carcinoma is more common in East Asia, is linked to smoking and tobacco use, more commonly involves the middle esophagus, and the precursor lesion is squamous dysplasia.Adenocarcinoma is more common in the United States and certain European countries, associated with obesity and gastroesophageal reflux disease (GERD), more commonly involves the distal esophagus, and the precursor lesion is Barrett's esophagus. Endoscopic surveillance with biopsy evaluation is the standard of care in high-risk groups. Endoscopic ablative therapies for early cancers have lower morbidity than surgery. Despite increased awareness, identification of high-risk groups and endoscopic surveillance, a large proportion of patients present with advanced cancers. Surgery and chemoradiation, either in neo-adjuvant or adjuvant setting, is the usual treatment for patients with advanced but resectable esophageal cancers. The prognosis and further management largely depends upon the pathologic tumor-node-metastasis (TNM) staging provided by the American Joint Committee on Cancer (AJCC) and the International Union against Cancer. Currently, the 7th edition of TNM staging system is being applied for prognostication and this is more focused on pathologic evaluation. Eighth edition of AJCC/UICC TNM staging has been introduced and will be implemented for clinical use in 2018.

show abstract

“…4 At present, the tumour-node-metastasis (TNM) staging system is the only well-recognized stratification system for treatment decisions. 5 However, TNM staging fails to assess the clinical outcome in a great number of patients. 6 Patients with the same stage category receive similar treatments, but their clinical outcome varies greatly.…”

Section: Introductionmentioning

confidence: 99%

Four transcription profile–based models identify novel prognostic signatures in oesophageal cancer

Liu

Fang

Han

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Oesophageal cancer (ESCA) is a clinically challenging disease with poor prognosis and health‐related quality of life. Here, we investigated the transcriptome of ESCA to identify high risk‐related signatures. A total of 159 ESCA patients of The Cancer Genome Atlas (TCGA) were sorted by three phases. In the discovery phase, differentially expressed transcripts were filtered; in the training phase, two adjusted Cox regressions and two machine leaning models were used to construct and estimate signatures; and in the validation phase, prognostic signatures were validated in the testing dataset and the independent external cohort. We constructed two signatures from three types of RNA markers by Akaike information criterion (AIC) and least absolute shrinkage and selection operator (LASSO) Cox regressions, respectively, and all candidate markers were further estimated by Random Forest (RFS) and Support Vector Machine (SVM) algorithms. Both signatures had good predictive performances in the independent external oesophageal squamous cell carcinoma (ESCC) cohort and performed better than common clinicopathological indicators in the TCGA dataset. Machine learning algorithms predicted prognosis with high specificities and measured the importance of markers to verify the risk weightings. Furthermore, the cell function and immunohistochemical (IHC) staining assays identified that the common risky marker FABP3 is a novel oncogene in ESCA.

show abstract

Evaluation of the 7^thedition of the TNM classification in patients with resected esophageal squamous cell carcinoma

Abstract: The 7(th) edition is considered to be valid for patients with resected ESCC. However, the histologic grade and cancer location were not prognostic factors for ESCC.

Cited by 39 publications

References 20 publications

Survival outcomes of 220 consecutive patients with three-staged thoracoscopic esophagectomy

Survival outcomes of 220 consecutive patients with three-staged thoracoscopic esophagectomy

Pathology of esophageal cancer and Barrett’s esophagus

Four transcription profile–based models identify novel prognostic signatures in oesophageal cancer

Contact Info

Product

Resources

About

Evaluation of the 7thedition of the TNM classification in patients with resected esophageal squamous cell carcinoma

Abstract: The 7(th) edition is considered to be valid for patients with resected ESCC. However, the histologic grade and cancer location were not prognostic factors for ESCC.

Cited by 39 publications

References 20 publications

Survival outcomes of 220 consecutive patients with three-staged thoracoscopic esophagectomy

Survival outcomes of 220 consecutive patients with three-staged thoracoscopic esophagectomy

Pathology of esophageal cancer and Barrett’s esophagus

Four transcription profile–based models identify novel prognostic signatures in oesophageal cancer

Contact Info

Product

Resources

About

Evaluation of the 7^thedition of the TNM classification in patients with resected esophageal squamous cell carcinoma